[{"id":"40b2e445-7d09-4c36-a4dc-82af89409797","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155033","created_at":"2021-12-13T14:12:41.079Z","updated_at":"2025-02-25T13:40:45.865Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma","source_id_and_acronym":"NCT05155033","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Proleukin (aldesleukin)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-21"},{"id":"838ef8af-7db3-4078-892e-5e0008843be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01005745","created_at":"2023-12-09T15:40:19.931Z","updated_at":"2025-02-25T13:59:46.111Z","phase":"","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT01005745","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/20/2009","start_date":" 10/20/2009","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-19"},{"id":"f64ea437-bbba-4636-a7d3-e32dea593ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821686","created_at":"2023-04-20T14:03:53.032Z","updated_at":"2025-02-25T15:20:25.754Z","phase":"Phase 1/2","brief_title":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","source_id_and_acronym":"NCT05821686","lead_sponsor":"Nova Scotia Health Authority","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/02/2026","start_date":" 01/02/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-12"},{"id":"71628f3d-27a7-487c-a8bd-86587a5fa22b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00026312","created_at":"2023-11-21T19:15:23.482Z","updated_at":"2025-02-25T16:50:44.915Z","phase":"Phase 3","brief_title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","source_id_and_acronym":"NCT00026312","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • NCR3LG1","pipe":"","alterations":" ","tags":["MYCN • NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1449","initiation":"Initiation: 10/18/2001","start_date":" 10/18/2001","primary_txt":" Primary completion: 01/12/2012","primary_completion_date":" 01/12/2012","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"6fb8362c-e7e1-47e4-848c-a1f5eb984935","acronym":"KEYNOTE-G08","url":"https://clinicaltrials.gov/study/NCT05824975","created_at":"2024-01-29T17:20:35.977Z","updated_at":"2025-02-25T16:18:44.543Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","source_id_and_acronym":"NCT05824975 - KEYNOTE-G08","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)"],"overall_status":"Recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 11/12/2025","primary_completion_date":" 11/12/2025","study_txt":" Completion: 04/24/2027","study_completion_date":" 04/24/2027","last_update_posted":"2024-11-25"},{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"9c16748b-c315-47c8-8692-ae028f1c0f22","acronym":"","url":"https://clinicaltrials.gov/study/NCT05194735","created_at":"2022-01-18T12:54:11.846Z","updated_at":"2024-07-02T16:35:00.596Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors","source_id_and_acronym":"NCT05194735","lead_sponsor":"Alaunos Therapeutics","biomarkers":" IFNG • IL6 • TNFA • IL2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["IFNG • IL6 • TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/04/2022","start_date":" 04/04/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-29"},{"id":"bda79509-21d5-4671-9520-4c738fdfa0e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02027935","created_at":"2021-05-24T22:52:50.882Z","updated_at":"2024-07-02T16:35:04.435Z","phase":"Phase 2","brief_title":"CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02027935","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • IL2 • MLANA","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2 • MLANA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2015","start_date":" 01/22/2015","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-05-10"},{"id":"e96ac04f-d494-4797-b71d-2048e4719923","acronym":"","url":"https://clinicaltrials.gov/study/NCT03318900","created_at":"2021-01-18T16:23:25.179Z","updated_at":"2024-07-02T16:35:05.191Z","phase":"Phase 1/2","brief_title":"T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03318900","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • PRAME • COL6A3","pipe":" | ","alterations":" PRAME expression","tags":["HLA-A • PRAME • COL6A3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRAME expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-08"},{"id":"2368e794-6a95-4b8e-bfab-f3ed9d06481c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01955460","created_at":"2021-01-18T08:52:28.248Z","updated_at":"2024-07-02T16:35:08.687Z","phase":"Phase 1","brief_title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT01955460","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NGFR • TGFA","pipe":" | ","alterations":" TILs","tags":["NGFR • TGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/15/2014","start_date":" 10/15/2014","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-19"},{"id":"a435469f-1cf1-4b7f-a476-32a5089846f8","acronym":"PIVOT IO 011","url":"https://clinicaltrials.gov/study/NCT04540705","created_at":"2021-01-18T21:43:33.570Z","updated_at":"2024-07-02T16:35:17.512Z","phase":"Phase 1","brief_title":"A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread","source_id_and_acronym":"NCT04540705 - PIVOT IO 011","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • axitinib • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-02-28"},{"id":"a555d72e-a833-4298-a799-b874d7c7606c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00338377","created_at":"2021-01-18T01:10:12.317Z","updated_at":"2024-07-02T16:35:20.425Z","phase":"Phase 2","brief_title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","source_id_and_acronym":"NCT00338377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1230","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 02/28/2030","primary_completion_date":" 02/28/2030","study_txt":" Completion: 02/28/2030","study_completion_date":" 02/28/2030","last_update_posted":"2024-02-07"},{"id":"7ff4baf4-9627-40b5-906f-346088349ad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03068624","created_at":"2021-01-18T15:07:02.967Z","updated_at":"2024-07-02T16:35:22.311Z","phase":"Phase 1","brief_title":"Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT03068624","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-25"},{"id":"bee6568b-22ed-4400-bf51-3257dce9d370","acronym":"","url":"https://clinicaltrials.gov/study/NCT02306954","created_at":"2021-01-18T10:55:08.267Z","updated_at":"2024-07-02T16:35:22.281Z","phase":"Phase 2","brief_title":"Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer","source_id_and_acronym":"NCT02306954","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-25"},{"id":"4e9aa552-a12c-4da8-8240-a354eef4c428","acronym":"","url":"https://clinicaltrials.gov/study/NCT00968760","created_at":"2021-01-18T03:46:34.880Z","updated_at":"2024-07-02T16:35:25.752Z","phase":"Phase 1","brief_title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","source_id_and_acronym":"NCT00968760","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2023-12-19"},{"id":"8faf38c0-263f-4288-a94e-9012fdb460fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01697527","created_at":"2021-03-25T16:35:32.028Z","updated_at":"2024-07-02T16:35:26.667Z","phase":"Phase 2","brief_title":"Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","source_id_and_acronym":"NCT01697527","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 11/02/2012","start_date":" 11/02/2012","primary_txt":" Primary completion: 11/02/2024","primary_completion_date":" 11/02/2024","study_txt":" Completion: 11/02/2025","study_completion_date":" 11/02/2025","last_update_posted":"2023-12-11"},{"id":"e83462de-87f7-4dab-90df-3962b5abd242","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823198","created_at":"2021-01-18T08:06:03.874Z","updated_at":"2024-07-02T16:35:30.156Z","phase":"Phase 1/2","brief_title":"Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies","source_id_and_acronym":"NCT01823198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • DNMT3A • TET2","pipe":" | ","alterations":" FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation","tags":["FLT3 • DNMT3A • TET2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • KIT mutation • DNMT3A mutation • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Proleukin (aldesleukin) • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2023-11-07"},{"id":"9eef6015-0524-41a2-ad75-5ca92817fddd","acronym":"PIVOT IO 001","url":"https://clinicaltrials.gov/study/NCT03635983","created_at":"2022-12-19T18:58:34.707Z","updated_at":"2024-07-02T16:35:33.001Z","phase":"Phase 3","brief_title":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","source_id_and_acronym":"NCT03635983 - PIVOT IO 001","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • bempegaldesleukin (NKTR-214)"],"overall_status":"Completed","enrollment":" Enrollment 783","initiation":"Initiation: 09/21/2018","start_date":" 09/21/2018","primary_txt":" Primary completion: 11/19/2021","primary_completion_date":" 11/19/2021","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2023-10-18"},{"id":"02699193-e287-431a-b255-1adc890318f2","acronym":"NCI-2018-00926","url":"https://clinicaltrials.gov/study/NCT03450122","created_at":"2021-01-19T15:37:56.641Z","updated_at":"2024-07-02T16:35:33.518Z","phase":"Phase 1","brief_title":"Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma","source_id_and_acronym":"NCT03450122 - NCI-2018-00926","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":"","alterations":" ","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/13/2018","start_date":" 09/13/2018","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-10-16"},{"id":"cd9c68a8-062c-418a-8a7a-3f467abc3209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639972","created_at":"2022-12-07T16:57:48.136Z","updated_at":"2024-07-02T16:35:33.860Z","phase":"Phase 1/2","brief_title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","source_id_and_acronym":"NCT05639972","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • E7 TCR cells • E7 TCR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-11"},{"id":"8f8e6e57-ee1a-46b1-bbd2-a9cebc9ec716","acronym":"SELECT","url":"https://clinicaltrials.gov/study/NCT00554515","created_at":"2021-01-18T02:01:16.594Z","updated_at":"2024-07-02T16:35:45.564Z","phase":"Phase 2","brief_title":"The High-Dose Aldesleukin (IL-2) \"Select\" Trial for Patients With Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT00554515 - SELECT","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" PD-L1 • CD276 • CA9","pipe":"","alterations":" ","tags":["PD-L1 • CD276 • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 10/31/2013","primary_completion_date":" 10/31/2013","study_txt":" Completion: 10/31/2013","study_completion_date":" 10/31/2013","last_update_posted":"2023-06-15"}]